As we prepare for Q1 2026, sponsors and CROs face a shifting global landscape for clinical trial comparator sourcing that focuses on sustainability, diversity and fair pricing. With our EcoVadis Platinum certification, women-owned business status and full scientific team in place, CSI is well placed to support our partner’s supply chains. 1. Supply-chain volatility is real Clinical supplies are increasingly challenged by geo-political pressures, export controls, and manufactu

By Clinical Services International As a proud Women-Owned Business , Clinical Services International (CSI)  is committed to transforming the global clinical supply landscape while championing gender equity and social responsibility. Founded on the principles of scientific excellence, ethical sourcing and diversity, CSI  stands at the forefront of pharmaceutical procurement and supply solutions for clinical trials worldwide. Women-owned businesses are vital to the global econo

As part of our ongoing commitment to excellence and continuous improvement, CSI is proud to announce the digitalization of our Quality Management System (QMS) through Simploud , a leading eQMS platform.   This transition marks an important milestone in enhancing both our customer and supplier experience, ensuring greater efficiency, transparency and compliance across our global operations.   Simploud ’s unified platform will streamline key quality processes (including CAPA ma

October is Breast Cancer Awareness Month and  Clinical Services International (CSI)  is wearing pink to show our solidarity with the cause. Pink is the colour of the ribbon that represents breast cancer awareness. Wearing pink on this day is a way to express support for breast cancer survivors, remember those lost to the disease and advocate for the progress in the fight against breast cancer. Reach out to CSI for your Breast Cancer studies, let's beat Breast Cancer together.

Client Overview A global biopharmaceutical company approached CSI to support a Phase III oncology study requiring Opdivo (nivolumab) as a comparator. The study spanned 4 countries across North America, Europe and Asia-Pacific, with a target enrolment of over 500 patients. The client’s main objective was to ensure timely delivery of branded Opdivo for multiple trial sites while maintaining transparent, full chain of custody and documentation.   Challenge There were several key

At CSI, we’ve built our reputation on being a trusted partner in advancing global health. Among our proudest achievements is our role in...

When it comes to sourcing medicines for Acute Myeloid Leukemia (AML), a supply partner with experience is imperative. At CSI, we’ve built...

At CSI, we understand the urgency and precision required in ophthalmology research. Among the most pressing areas is wet age-related...

Strategy Partnerships for Budget Value As we enter Q4, many clinical operations teams face the familiar challenge of budget utilization....

Rare disease clinical trials present a distinct set of challenges that make sourcing strategies critical to study success. With fewer...

On November 4th-5th, join CSI’s Managing Director, Vanessa Dekou and Head of Operations, North America, Jonathan Miller at the...